Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREAT trial: mepolizumab vs omalizumab in severe paediatric asthma
2019-004085-17Phase 3Unknown
- Sponsor
- Imperial College London
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in asthma comparing Mepolizumab arm with Omalizumab arm (2 arms). Primary endpoint: 52-week asthma exacerbation rate. Status: unknown.
02
Drugs
mepolizumabomalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2019-004085-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004085-17.